Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20480384 | 0.81 | CAMK2A (0.42) | KMT2AMEN1LMNACYP1A2ALDH1A1 | |
| SCHEMBL27561346 | 0.79 | CYSLTR2 (0.48) | LMNACYP1A2PTGDR2KDM4E | |
| SCHEMBL30009200 | 0.79 | BACE1 (0.46) | KDRHTTCYP1A2MAPTAKR1B1 | |
| SCHEMBL28500268 | 0.79 | TLR9 (0.42) | KMT2AMEN1F2LMNACHRM2 | |
| SCHEMBL6299614 | 0.78 | HSD17B10 (0.38) | KMT2AMEN1LMNAHSD17B14GABRA5 | |
| SCHEMBL140815 | 0.77 | CYP1A2 (0.65) | KMT2AMEN1CYP1A2ALDH1A1AKR1B1 | |
| Anthracene SCHEMBL10418177 | 0.76 | CYP1A2 (0.59) | KMT2AMEN1CYP1A2ALDH1A1AKR1B1 | |
| SCHEMBL3361769 | 0.73 | MGAM (0.58) | KMT2AMEN1F2LMNACHRM2 | |
| Acetic Acid SCHEMBL27459479 | 0.72 | CYP1A2 (0.64) | KMT2AMEN1CYP1A2ALDH1A1MAPT | |
| SCHEMBL14610935 | 0.71 | CCR1 (0.54) | LMNAGABRA5GABRB2HSD17B10CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6841555-B2 | Lavendamycin analogs, quinoline-5,8-diones and methods of using them | BALL STATE UNIVERSITY (US) | 2005-01-11 | — | — | US | disclosed |
| US-20040248922-A1 | LAVENDAMYCIN ANALOGS, QUINOLINE-5,8-DIONES AND METHODS OF USING THEM | BALL STATE UNIVERSITY | 2004-12-09 | — | — | US | disclosed |
| US-6444684-B1 | ANTIBIOTIC AND ANTI-HIV REVERSE TRANSCRIPTASE (HIV-RT) ACTIVITY; TREATING HIV INFECTION AND ALSO WITH AZT; ANTITUMOR | BALL STATE UNIVERSITY | 2002-09-03 | — | — | US | disclosed |
| US-6030983-A | ANTITUMOR AND -CARCINOGENIC AGENTS; ANTIBIOTICS; BACTERICIDES; VIRICIDES; PARACITICIDES; ENZYME INHIBITORS; POLYMERASES; FARNESYL-PROTEIN TRANSFERASE; RAS PROTEINS | BALL STATE UNIVERSITY (US) | 2000-02-29 | — | — | US | disclosed |
| US-5712289-A | ANTITUMOR AGENTS, INTERMEDIATES FOR LAVENDAMYCINS | BALL STATE UNIVERSITY (US) | 1998-01-27 | — | — | US | disclosed |
| EP-0701557-A4 | LAVENDAMYCIN ANALOGS, THEIR USE AND PREPARATION | BEHFOROUZ MOHAMMAD (US) | 1997-07-09 | — | — | EP | disclosed |
| US-5646150-A | ADMINISTERING AS ANTITUMOR AGENT, ANTIPROTOZOA AGENT, VIRICIDE, PARASITICIDE, OR BACTERICIDE | BALL STATE UNIVERSITY (US) | 1997-07-08 | — | — | US | disclosed |
| US-5525611-A | ANTITUMOR AGENT, BACTERICIDES, VIRICIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1996-06-11 | — | — | US | disclosed |
| EP-0701557-A1 | LAVENDAMYCIN ANALOGS, THEIR USE AND PREPARATION | BEHFOROUZ, Mohammad (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1994029308-A1 | LAVENDAMYCIN ANALOGS, THEIR USE AND PREPARATION | BEHFOROUZ MOHAMMAD (US) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248922-A1 | LAVENDAMYCIN ANALOGS, QUINOLINE-5,8-DIONES AND METHODS OF USING THEM | LSS, CYP51A1, COX5A | KMT2A 1940/4885MEN1 2336/4885F2 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.